Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NASDAQ:MTEX NYSE:NBY NASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.01-2.9%$0.96$0.61▼$6.00$15.68M0.04517,880 shs366,485 shsMTEXMannatech$8.74+6.6%$9.09$7.00▼$16.49$15.59M0.8413,785 shs7,901 shsNBYNovaBay Pharmaceuticals$0.59+2.2%$0.61$0.36▼$1.01$3.45M0.44111,699 shs30,504 shsPRPHProPhase Labs$0.33-9.3%$0.38$0.22▼$3.08$14.94M-0.48986,704 shs785,137 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics-2.88%-0.98%+1.00%-9.01%-81.50%MTEXMannatech+6.62%+8.54%-3.98%-9.73%+14.89%NBYNovaBay Pharmaceuticals+2.15%-11.73%-5.06%+1.18%-1.08%PRPHProPhase Labs-9.34%-30.04%-19.22%-1.39%-89.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics2.7272 of 5 stars3.54.00.00.02.10.01.3MTEXMannatechN/AN/AN/AN/AN/AN/AN/AN/ANBYNovaBay Pharmaceuticals1.6118 of 5 stars3.50.00.00.00.60.01.3PRPHProPhase Labs0.9293 of 5 stars0.05.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 3.00Buy$9.00791.09% UpsideMTEXMannatech 0.00N/AN/AN/ANBYNovaBay Pharmaceuticals 3.00Buy$0.8543.22% UpsidePRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NBY, PRPH, ALLR, and MTEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/28/2025ALLRAllarity TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AMTEXMannatech$117.87M0.14$2.28 per share3.84$4.57 per share1.91NBYNovaBay Pharmaceuticals$9.78M0.35N/AN/A$4.25 per share0.14PRPHProPhase Labs$6.77M2.00N/AN/A$0.25 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)MTEXMannatech$2.49M-$0.10N/A∞N/A-0.19%-2.56%-0.57%8/12/2025 (Estimated)NBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/APRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)Latest NBY, PRPH, ALLR, and MTEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PRPHProPhase Labs-$0.15N/AN/AN/A$3.55 millionN/A5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/A5/13/2025Q1 2025MTEXMannatechN/A-$0.80N/A-$0.80N/A$26.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AMTEXMannatechN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.662.66MTEXMannatech0.461.180.65NBYNovaBay PharmaceuticalsN/A1.150.91PRPHProPhase Labs0.301.030.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%MTEXMannatech12.98%NBYNovaBay Pharmaceuticals23.25%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%MTEXMannatech41.50%NBYNovaBay Pharmaceuticals0.10%PRPHProPhase Labs9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.08 million15.07 millionNot OptionableMTEXMannatech2501.90 million1.11 millionNot OptionableNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableNBY, PRPH, ALLR, and MTEX HeadlinesRecent News About These CompaniesProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy StatementJuly 29, 2025 | globenewswire.comProPhase Labs announces closing of $3M senior secured convertible notesJuly 25, 2025 | msn.comProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes FinancingJuly 23, 2025 | globenewswire.comProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury InitiativeJuly 21, 2025 | globenewswire.comProPhase Labs Regains Nasdaq Compliance with New AppointmentJuly 1, 2025 | tipranks.comProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - MorningstarJune 27, 2025 | morningstar.comMProPhase Labs Inc. Receives 180-Day Extension from Nasdaq to Regain Bid Price ComplianceJune 26, 2025 | quiverquant.comQProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price RuleJune 26, 2025 | globenewswire.comProphase Labs Appoints Carolina Abenante as DirectorJune 25, 2025 | tipranks.comProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal CancerJune 17, 2025 | globenewswire.comProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic PlatformJune 6, 2025 | globenewswire.comProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025May 21, 2025 | seekingalpha.comEarnings call transcript: ProPhase Labs beats Q1 2025 EPS forecast, stock risesMay 21, 2025 | investing.comProPhase Labs Inc (PRPH) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ChallengesMay 21, 2025 | finance.yahoo.comProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2025 Earnings Call TranscriptMay 21, 2025 | msn.comProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | seekingalpha.comProPhase Labs Q1 2025 Earnings PreviewMay 19, 2025 | msn.comProPhase Labs's Earnings OutlookMay 19, 2025 | benzinga.comProPhase Labs Delays Form 10-Q FilingMay 16, 2025 | tipranks.comProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025May 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBY, PRPH, ALLR, and MTEX Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.01 -0.03 (-2.88%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.01 +0.00 (+0.50%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Mannatech NASDAQ:MTEX$8.74 +0.54 (+6.62%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$8.30 -0.44 (-5.07%) As of 08/1/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.NovaBay Pharmaceuticals NYSE:NBY$0.59 +0.01 (+2.15%) As of 08/1/2025 04:00 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.ProPhase Labs NASDAQ:PRPH$0.33 -0.03 (-9.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.32 0.00 (-0.95%) As of 08/1/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
